Page last updated: 2024-11-11

24,25-dihydroxyvitamin d 3

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth

Description

24,25-Dihydroxyvitamin D 3: A physiologically active metabolite of VITAMIN D. The compound is involved in the regulation of calcium metabolism, alkaline phosphatase activity, and enhancing the calcemic effect of CALCITRIOL. [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID6434253
CHEMBL ID47183
SCHEMBL ID1242915
MeSH IDM0023988

Synonyms (26)

Synonym
9,10-secocholesta-5,7,10(19)-triene-3,24,25-triol, (3-beta,5z,7e)-
(3beta,5z,7e)-9,10-secocholesta-5,7,10(19)-triene-3,24,25-triol
einecs 254-749-5
24,25-dihydroxyvitamin d 3
HY-76915
24, 25-dihydroxy vd3
24, 25-dihydroxy vitamin d3
CHEMBL47183
(6r)-6-[(1r,3as,4e,7ar)-4-[(2z)-2-[(5s)-5-hydroxy-2-methylidenecyclohexylidene]ethylidene]-7a-methyl-2,3,3a,5,6,7-hexahydro-1h-inden-1-yl]-2-methylheptane-2,3-diol
NCGC00186631-01
40013-87-4
unii-0axx2v8l5z
0axx2v8l5z ,
CS-0806
secalciferol, (24rs)-
2,3-heptanediol, 2-methyl-6-((1r,3as,4e,7ar)-octahydro-4-((2z)-2-((5s)-5-hydroxy-2-methylenecyclohexylidene)ethylidene)-7a-methyl-1h-inden-1-yl)-, (6r)-
SCHEMBL1242915
24,25-dihydroxy vd3
AC-26353
AKOS025401845
Q139001
24,25-dihydroxyvd3
F84842
AS-79839
DTXSID501028177
PD015535

Research Excerpts

Toxicity

ExcerptReferenceRelevance
" Though there was a stable tendency for hyperphosphatemia and altered blood calcium concentrations, the 24,25-DOHK formulations under test, unlike 1-OXK and 1,25-DOXK, displayed no toxic properties on the kidney, heart and aorta and produced a mineralizing effect on bone tissue in the acute period."( [The toxicity of different forms of 24,25-dihydroxycholecalciferol preparations in rats].
Trishkin, SV,
)
0.13

Pharmacokinetics

ExcerptReferenceRelevance
" In the calcium-supplemented healthy subjects, the pharmacokinetic quantities were not significantly different while the area under the serum concentration-time curve and the estimated bioavailability were significantly decreased."( Human pharmacokinetics of orally administered (24 R)-hydroxycalcidiol.
Barto, R; Greuter, H; Leeuwenkamp, OR; Lips, P; Netelenbos, JC; van der Vijgh, WJ; van der Wiel, HE, 1993
)
0.29

Bioavailability

ExcerptReferenceRelevance
" Bioavailability as estimated from this plateau level was approximately 70%."( Pharmacokinetics of 24,25-dihydroxyvitamin D3 in humans.
Jongen, M; Lips, P; Netelenbos, JC; Postma, GJ; van der Vijgh, WJ, 1989
)
0.28
" In the calcium-supplemented healthy subjects, the pharmacokinetic quantities were not significantly different while the area under the serum concentration-time curve and the estimated bioavailability were significantly decreased."( Human pharmacokinetics of orally administered (24 R)-hydroxycalcidiol.
Barto, R; Greuter, H; Leeuwenkamp, OR; Lips, P; Netelenbos, JC; van der Vijgh, WJ; van der Wiel, HE, 1993
)
0.29
"We evaluated the long-term bioavailability and metabolism of a single po or intramuscular (im) high dose of ergocalciferol (D₂) or D₃."( Long-term bioavailability after a single oral or intramuscular administration of 600,000 IU of ergocalciferol or cholecalciferol: implications for treatment and prophylaxis.
Carlucci, L; Cipriani, C; McMahon, DJ; Minisola, S; Nieddu, L; Pepe, J; Piemonte, S; Romagnoli, E; Russo, S; Singh, R, 2013
)
0.39

Dosage Studied

ExcerptRelevanceReference
" Through the dosing period, serum calcium, phosphorus, alkaline phosphatase, and creatinine levels were not altered."( Increased bone volume and reduced bone turnover in vitamin D-replete rabbits by the administration of 24R,25-dihydroxyvitamin D3.
Hirai, T; Kurokawa, T; Nakamura, T; Orimo, H; Suzuki, K, 1992
)
0.28
" The time course and dose-response curves of PTH-stimulated cAMP accumulation were studied in dog and rat PTC."( Dog and rat kidney proximal tubule cells in culture: responses to parathyroid hormone.
Kovacs, K; Rao, LG; Yau, CH, 1989
)
0.28
" Only the daily dosage of 250,000 IU caused significant increases of concentrations of vitamin D or 25-hydroxyvitamin D in plasma."( Effects of dietary vitamin D3 on concentrations of vitamin D and its metabolites in blood plasma and milk of dairy cows.
Beitz, DC; Horst, RL; Littledike, ET; McDermott, CM, 1985
)
0.27
" Rapidly growing male rats were dosed with 24,25-dihydroxyvitamin D3 orally until plasma concentrations of 24,25-dihydroxyvitamin D3 were at steady state."( Metabolism and pharmacokinetics of 24,25-dihydroxyvitamin D3 in the vitamin D3-replete rat.
DeLuca, HF; Jarnagin, K; Phelps, M; Zeng, SY, 1985
)
0.27
" The dose-response curve was biphasic for all compounds studied; for 1,25(OH)2D3 initial stimulation of transport was detected at only 30 pM [the plasma concentration of 1,25(OH)2D3 is normally 125 pM] while maximal stimulation was 154% above control at a concentration of 650 pM."( Biological activity of vitamin D metabolites and analogs: dose-response study of 45Ca transport in an isolated chick duodenum perfusion system.
Norman, AW; Yoshimoto, Y, 1986
)
0.27
" The rates of osteoid maturation and initial mineralization increased during repletion with 24,25(OH)2D3 at both dosage levels."( 24,25(OH)2D3, bone formation, and bone resorption in vitamin D-deficient, azotemic rats.
Baylink, DJ; Goodman, WG; Sherrard, DJ, 1984
)
0.27
" During treatment with 1,25-dihydroxy vitamin D3 progressive reduction in dosage was required in the majority of patients because of hypercalcaemia, which was rapidly corrected by stopping treatment for a few days."( Long-term effects of 1,25-dihydroxy vitamin D3 and 24,25-dihydroxy vitamin D3 in renal osteodystrophy.
Adami, S; Catto, GR; Edward, N; Fraser, RA; Muirhead, N; O'Riordan, JL; Sandler, LM, 1982
)
0.26
" At equimolar dosage 1,25-dihydroxycholecalciferol had a potent stimulatory effect on bone resorption."( Suppressive effects of 24,25-dihydroxycholecalciferol on bone resorption induced by acute bilateral nephrectomy in rats.
Balsan, S; Bourdeau, A; Cournot-Witmer, G; Fischer, JA; Heynen, G; Pavlovitch, JH, 1981
)
0.26
" Treatment at this dosage of 24,25(OH)2D3, which increased plasma levels within the physiological range, conferred no measurable long-term benefit on our patients."( Long-term treatment of osteoporosis with 24,25 dihydroxycholecalciferol.
Elsasser, U; Green, JR; Hesp, R; Hulme, P; Kanis, JA; Mawer, EB; Meunier, PJ; Reeve, J; Russell, RG; Tellez, M; Williams, D; Wootton, R, 1982
)
0.26
" Subsequently, patients were assigned randomly to 6 months further treatment either with 1 alpha-(OH)D3 alone (Group A) or with 1 alpha-(OH)D3 plus a high dosage of 24,25-(OH)2D3 (50 micrograms orally, twice weekly) (Group B)."( Effects of 24R,25-dihydroxyvitamin D3 in combination with 1 alpha-hydroxyvitamin D3 in predialysis renal insufficiency: biochemistry and histomorphometry of cancellous bone.
Birkenhäger, JC; Birkenhäger-Frenkel, DH; Eijgelsheim, JJ; Mulder, PG; Nigg, AL; Pols, HA; Schot, R; Weimar, W; Zeelenberg, J, 1995
)
0.29
" The control group received calcium carbonate (maximal dosage of 1 g x 3)."( 24,25-dihydroxy vitamin D3 treatment inhibits parathyroid-stimulated adenylate cyclase in iliac crest biopsies from uremic patients.
Aarseth, HP; Ganss, R; Gautvik, KM; Gordeladze, JO; Haug, E; Mortensen, BM,
)
0.13
" Vascular perfusion with a range of 1,25-(OH)2D3 concentrations yielded an apparent biphasic dose-response curve."( Apparent nonnuclear regulation of intestinal phosphate transport: effects of 1,25-dihydroxyvitamin D3,24,25-dihydroxyvitamin D3, and 25-hydroxyvitamin D3.
Nemere, I, 1996
)
0.29
" The above metabolites, except 24,25-dihydroxyvitamin D(3) 3-glucuronide, were obtained from rats dosed with 25-hydroxyvitamin D(3)."( Characterization of new conjugated metabolites in bile of rats administered 24,25-dihydroxyvitamin D(3) and 25-hydroxyvitamin D(3).
Hatakeyama, S; Higashi, T; Hiyamizu, H; Iwabuchi, Y; Kikuchi, R; Kubodera, N; Miura, K; Ooi, H; Shimada, K, 2000
)
0.31
" Both isolated enterocytes and the perfused duodenal loop system exhibited apparent biphasic dose-response curves for 1,25(OH)2D3-stimulated 32P uptake and transport, and inhibition of stimulation by 24,25(OH)2D3."( 1,25(OH)2D3-mediated phosphate uptake in isolated chick intestinal cells: effect of 24,25(OH)2D3, signal transduction activators, and age.
Nemere, I; Zhao, B, 2002
)
0.31
" 1,25-(OH)2D3 rapidly stimulated PHF release with enhanced sensitivity in SHR versus WKY cultures indicated by a leftward shift in the dose-response curve, whereas 24,25-dihydroxyvitamin D3 (24,25-(OH)2D3) had the converse effect."( Regulation of parathyroid hypertensive factor secretion by vitamin D3 analogs in parathyroid cells derived from spontaneously hypertensive rats.
Benishin, CG; Nemere, I; Sutherland, SK, 2005
)
0.33
" Dose-response studies indicated a biphasic curve with optimal stimulation at 300 pM 1,25(OH)(2)D(3) and inhibition at 600 pM seco-steroid."( Phosphate uptake in chick kidney cells: effects of 1,25(OH)2D3 and 24,25(OH)2D3.
Khanal, RC; Nemere, I; Smith, NM, 2007
)
0.34
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (4)

Assay IDTitleYearJournalArticle
AID1347082qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347086qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347083qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID227718Binding energy by using the equation deltaG obsd = -RT ln KD1984Journal of medicinal chemistry, Dec, Volume: 27, Issue:12
Functional group contributions to drug-receptor interactions.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (765)

TimeframeStudies, This Drug (%)All Drugs %
pre-1990402 (52.55)18.7374
1990's196 (25.62)18.2507
2000's77 (10.07)29.6817
2010's83 (10.85)24.3611
2020's7 (0.92)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials33 (4.04%)5.53%
Reviews55 (6.74%)6.00%
Case Studies9 (1.10%)4.05%
Observational1 (0.12%)0.25%
Other718 (87.99%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]